Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  The Quarterly Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 16172574
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?

  2002cited by this paper
• Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease.

  2001cited by this paper
• Comparison of Tc-99m Sestamibi and Tl-201 Uptake in Multiple Myeloma

  2001cited by this paper
• Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma

  2001cited by this paper
• Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate

  2001cited by this paper
• Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up

  2001cited by this paper
• Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation

  2001cited by this paper
• Multidrug resistance in haematological malignancies

  2000cited by this paper
• Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy.

  1999cited by this paper
• Clinical imaging of multidrug resistance in cancer.

  1999cited by this paper
• Drug resistance in multiple myeloma.

  1999cited by this paper
• Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

  1998cited by this paper
• P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy.

  1998cited by this paper
• Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?

  1998cited by this paper
• Different patterns of technetium-99m sestamibi uptake in multiple myeloma

  1998cited by this paper
• In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients

  1997cited by this paper
• Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma.

  1997cited by this paper
• Plasma cell P170 expression and response to treatment in multiple myeloma.

  1996cited by this paper
• The use of 99mTc-MIBI scanning in multiple myeloma.

  1996cited by this paper
• Technetium-99m-sestamibi uptake in myeloma.

  1996cited by this paper
• 99Tcm‐sestamibi as an agent for imaging P‐glycoprotein-mediated multi‐drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxirubicin‐resistant variant

  1995cited by this paper
• Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

  1993cited by this paper
• Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts.

  1992cited by this paper
• Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.

  1990cited by this paper
• Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence.

  1990cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper

• F-18 FDG PET/CT and F-18 FLT PET/CT as predictors of outcome in patients with multiple myeloma. A pilot study.

  2021cites this paper
• In vitro comparison of the cytotoxic effects of lenalidomide alone and in combination with verapamil on myeloma cell line

  2021cites this paper
• Multiple myeloma in a patient with suspected hyperparathyroidism

  2019cites this paper
• Efforts to visually match 5- and 60-minute post-stress images following a single injected dose of sestamibi clearly demonstrate changes in sestamibi distribution: Demonstrating once and for all clinical recognition that sestamibi redistributes

  2019cites this paper
• Holding big Pharma Accountable

  2019cites this paper
• Prediction and evaluation of neoadjuvant chemotherapy using the dual mechanisms of 99mTc-MIBI scintigraphy in patients with osteosarcoma

  2019cites this paper
• USVAH Study Demonstrates Statistically Significant Improvement in Diagnosis and Care of U.S Veterans Using FMTVDM – FHRWW©℗ “Quantitative” Nuclear Imaging. The Era of Truly Quantitative Stress- First, Stress-Only Imaging has begun!

  2018influential citation
• 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study

  2015cites this paper
• The role of P-glycoprotein in drug resistance in multiple myeloma

  2015cites this paper
• Radiopharmaceuticals for the Imaging of ABC-Transporter-Mediated Multidrug Resistance in Cancer

  2015cites this paper
• Imaging physiological ABC transporter expression and its relation to disease using Tc-99m-hexakis-methoxy-isobutyl isonitrile (Tc-99m-MIBI)

  2015cites this paper
• Tc 99m Sestamibi Scanning in Multiple Myeloma--a New look with SPECT-CT.

  2014cites this paper
• 99mTc Sestamibi as a Prognostic Factor of Response to First-Line Therapy and Outcome in Patients With Malignant Lymphoma

  2013cites this paper
• The role of imaging techniques in the management of multiple myeloma

  2012cites this paper
• Oncologic Applications of Sestamibi: In Vivo Imaging of Multi-Drug Resistance

  2012cites this paper
• A single (99m)Tc-MIBI study to predict response to neoadjuvant treatment in sarcoma patiens.

  2011cites this paper
• Imaging of multidrug resistance in cancer

  2011cites this paper
• Fleming-Harrington Redistribution Wash-in Washout (FHRWW): The Platinum Standard for Nuclear Cardiology

  2011cites this paper
• Nuclear medicine in myeloma: the state of the science and emerging trends.

  2011cites this paper
• Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals.

  2010cites this paper
• Nuclear medicine in multiple myeloma -- more than diagnosis.

  2010cites this paper
• International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

  2009cites this paper
• Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers.

  2009cites this paper
• 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients.

  2009cites this paper
• Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer

  2008cites this paper
• Technetium-99m-sestamibi scintigraphy in gynecological cancer imaging.

  2008cites this paper
• 18 F-FDG PET / CT , 99 mTc-MIBI , and MRI in Evaluation of Patients with Multiple Myeloma

  2008cites this paper
• 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma

  2008cites this paper
• Técnicas de imagen en el diagnóstico de metástasis óseas

  2007cites this paper
• Technetium‐99m sestamibi scintigraphy is sensitive and specific for the staging and the follow‐up of patients with multiple myeloma: a multicentre study on 397 scans

  2007cites this paper
• [Imaging techniques in the evaluation of metastatic bone disease].

  2007cites this paper
• Nuclear imaging in cancer theranostics.

  2007cites this paper
• Diffuse tracer uptake in scintimammography: not as nonspecific or benign as originally believed?

  2006cites this paper
• Use of 99mTc-sestamibi scintigraphy in multiple myeloma.

  2006cites this paper
• Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease.

  2006cites this paper
• Technetium 99m sestamibi in multiple myeloma.

  2005cites this paper